ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Dechra Pharmaceuticals PLC Directorate Change (0995U)

31/03/2021 9:00am

UK Regulatory


Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Dechra Pharmaceuticals Charts.

TIDMDPH

RNS Number : 0995U

Dechra Pharmaceuticals PLC

31 March 2021

31 March 2021

Dechra(R) Pharmaceuticals PLC

(Dechra, the Company or the Group)

Appointment of Denise Goode as Non-Executive Director of Dechra Pharmaceuticals PLC

Dechra is pleased to announce that, with effect from 26 April 2021, Denise Goode will take up a new position as a Non-Executive Director of the Company. Denise will be a member of the Group's Audit, Remuneration and Nomination Committees with the intention that she will be appointed as Chairman of the Audit Committee upon Julian Heslop's retirement as Audit Committee Chairman following the 2021 Annual General Meeting.

Denise brings a wealth of financial, commercial and life science industry experience, both from her extensive career as a senior executive and from board roles held since 2008. She has a deep understanding of the pharmaceuticals sector and is highly experienced in business development.

Denise is currently a Non-Executive Director of Abliva AB, a NASDAQ Sweden listed company, where she is Chair of the Remuneration Committee and a member of the Audit Committee. She is also Vice President, Business Development at AnaMar AB, a Swedish based private company. In 2014 Denise established QED Life Sciences Limited, through which as CEO she advises and supports the strategic direction of biotech companies. Prior to this, Denise was Chair of the Audit Committee at Oxford Bioscience Network from 2014 to 2017 and of AstraZeneca Ireland Operations Ltd from 2008 to 2013. Over her 20 year global career with AstraZeneca Pharmaceuticals PLC, Denise held senior leadership roles within the finance and commercial activities of the global entity. She is a Fellow of the Institute of Chartered Accountants in England and Wales.

Commenting on the appointment Tony Rice, Chairman, Dechra Pharmaceuticals said:

" On behalf of the Board and all stakeholders I am delighted to welcome Denise to Dechra. She will add significant pharmaceutical and financial experience and capabilities to the team as well as providing continuity during the next phase of Dechra's growth and development."

There are no other disclosures to be made in respect of Denise Goode, pursuant to Listing Rule 9.6.13R.

 
 Enquiries to: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive Officer 
 Office: +44 (0) 1606 814 730 
 e-mail: corporate.enquiries@dechra.com 
 
 TooleyStreet Communications Ltd 
 Fiona Tooley, Director 
  Mobile: +44 (0) 7785 703 523 
  e-mail: fiona@tooleystreet.com 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

For more information please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFIFFDVEILVIL

(END) Dow Jones Newswires

March 31, 2021 04:00 ET (08:00 GMT)

1 Year Dechra Pharmaceuticals Chart

1 Year Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock